Pituitary adenylate cyclase activating polypeptide is protective in bilateral carotid occlusion-induced retinal lesion in rats

被引:52
作者
Atlasz, Tamas
Babai, Norbert
Kiss, Peter
Reglodi, Dora
Tamas, Andrea
Szabadfi, Krisztina
Toth, Gabor
Hegyi, Orsolya
Lubics, Andrea
Gabriel, Robert
机构
[1] Univ Pecs, Fac Med, Dept Anat, H-7624 Pecs, Hungary
[2] Univ Pecs, Dept Expt Zool & Neurobiol, Pecs, Hungary
[3] Univ Szeged, Dept Med Chem, Szeged, Hungary
基金
匈牙利科学研究基金会;
关键词
neuropeptide; neuroprotection; photoreceptor; ischemic injury;
D O I
10.1016/j.ygcen.2006.12.022
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pituitary adenylate cyclase activating popypeptide (PACAP) is a pleiotropic neuropeptide, exerting neurotrophic and neuroprotective effects in numerous models of in vitro and in vivo nervous injuries. The aim of the present study was to investigate whether PACAP is neuroprotective in ischemic retinal damage. Adult male Wistar rats underwent bilateral carotid occlusion and PACAP was administered Unilaterally into the vitreous body immediately following carotid Occlusion. Retinas were analyzed three weeks after the injury. It was found that bilateral carotid Occlusion led to a severe degeneration of all retinal layers. PACAP treatment significantly ameliorated the carotid occlusion-induced retinal damage: the overall thickness of the retina was significantly more than in control carotid occluded animals and the morphological characteristics of the photoreceptors showed nearly normal appearance. The outer plexiform layer remained discernible and the inner and outer nuclear layers were significantly thicker than in control animals. In summary, Our present study provides evidence, for the first time, that PACAP attenuates ischemic retinal degeneration. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:108 / 114
页数:7
相关论文
共 71 条
[1]   Neuropeptide mimetics and antagonists in the treatment of inflammatory disease: Focus on VIP and PACAP [J].
Abad, C ;
Gomariz, RP ;
Waschek, JA .
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2006, 6 (02) :151-163
[2]   Perspectives on pituitary adenylate cyclase activating polypeptide (PACAP) in the neuroendocrine, endocrine, and nervous systems [J].
Arimura, A .
JAPANESE JOURNAL OF PHYSIOLOGY, 1998, 48 (05) :301-331
[3]   Degree of damage compensation by various PACAP treatments in monosodium glutamate-induced retinal degeneration [J].
Babai, N ;
Atlasz, T ;
Tamás, A ;
Reglodi, D ;
Tóth, G ;
Kiss, P ;
Gábriel, R .
NEUROTOXICITY RESEARCH, 2005, 8 (3-4) :227-233
[4]  
Bagnoli P, 2003, HISTOL HISTOPATHOL, V18, P1219, DOI 10.14670/HH-18.1219
[5]   RETINAL ISCHEMIA INDUCED BY OCCLUSION OF BOTH COMMON CAROTID ARTERIES IN RATS AS DEMONSTRATED BY ELECTRORETINOGRAPHY [J].
BLOCK, F ;
SCHWARZ, M ;
SONTAG, KH .
NEUROSCIENCE LETTERS, 1992, 144 (1-2) :124-126
[6]   Pituitary adenylate cyclase-activating polypeptide (PACAP) can act as determinant of the tyrosine hydroxylase phenotype of dopaminergic cells during retina development [J].
Borba, JC ;
Henze, IP ;
Silveira, MS ;
Kubrusly, RCC ;
Gardino, PF ;
de Mello, MCF ;
Hokoç, JN ;
de Mello, FG .
DEVELOPMENTAL BRAIN RESEARCH, 2005, 156 (02) :193-201
[7]   Functional and molecular expression of PACAP/VIP receptors in the rat retina [J].
D'Agata, V ;
Cavallaro, S .
MOLECULAR BRAIN RESEARCH, 1998, 54 (01) :161-164
[8]   Inhibition of interferon (IFN) γ-induced Jak-STAT1 activation in microglia by vasoactive intestinal peptide -: Inhibitory effect on CD40, IFN-induced protein-10, and inducible nitric-oxide synthase expression [J].
Delgado, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (30) :27620-27629
[9]   Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the production of inflammatory mediators by activated microglia [J].
Delgado, M ;
Leceta, J ;
Ganea, D .
JOURNAL OF LEUKOCYTE BIOLOGY, 2003, 73 (01) :155-164
[10]   Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the MEKK1/MEK4/JNK signaling pathway in endotoxin-activated microglia [J].
Delgado, M .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 293 (02) :771-776